The Atherectomy Devices Market size was estimated at USD 1.17 billion in 2025 and expected to reach USD 1.25 billion in 2026, at a CAGR of 7.85% to reach USD 1.98 billion by 2032.

Atherectomy devices are specialized endovascular tools used to remove or modify atherosclerotic plaque in peripheral and coronary arteries, supporting vessel preparation, luminal gain, and improved blood flow in patients with occlusive vascular disease. Demand for these devices is closely linked to the global burden of peripheral artery disease, coronary artery disease, diabetes, chronic kidney disease, smoking-related vascular injury, and population aging. In clinical practice, directional, rotational, orbital, laser, and aspiration atherectomy systems are used selectively based on lesion morphology, calcification severity, vessel size, thrombotic burden, operator experience, and the planned adjunctive therapy, including balloon angioplasty, drug-coated technologies, or stenting.

The atherectomy devices landscape is shaped by the need to treat complex calcified lesions while reducing procedural complications such as dissection, perforation, distal embolization, restenosis, and repeat revascularization. Healthcare systems are prioritizing minimally invasive vascular interventions that shorten recovery times, preserve limbs, and reduce the clinical consequences of advanced peripheral artery disease. As a result, the market environment is increasingly focused on evidence-based lesion preparation, improved device deliverability, embolic protection strategies, imaging-guided therapy, and standardized operator training.

The atherectomy devices landscape is undergoing a significant transformation as vascular specialists shift from a purely lumen-opening approach toward precision vessel preparation. In heavily calcified peripheral and coronary lesions, calcium modification has become central to procedural planning because calcification can impair balloon expansion, stent delivery, drug uptake, and long-term vessel patency. This shift has increased clinical attention on atherectomy as part of an integrated treatment strategy rather than as a stand-alone intervention.

Another important shift is the expansion of image-guided intervention. Intravascular ultrasound, angiographic assessment, lesion scoring, and cross-sectional imaging are increasingly used to characterize plaque composition, calcium arc, vessel diameter, and treatment endpoints. These tools support more consistent device selection and help reduce unnecessary passes or excessive tissue removal. At the same time, care delivery is moving toward outpatient and ambulatory vascular settings in several countries, creating demand for atherectomy platforms that are efficient, predictable, and compatible with streamlined procedural workflows.

Regulatory scrutiny and reimbursement discipline are also reshaping adoption. Health authorities and payers are emphasizing clinical evidence, patient selection, real-world safety data, and comparative outcomes. This has encouraged the development of training programs, post-procedure surveillance, and clearer documentation of procedural rationale, particularly for peripheral artery disease interventions involving complex femoropopliteal, tibial, and below-the-knee lesions.

Artificial intelligence is beginning to influence atherectomy devices through adjacent capabilities in vascular imaging, procedural planning, workflow automation, and outcomes monitoring. AI-enabled image analysis can assist clinicians in identifying calcification patterns, estimating vessel dimensions, segmenting lesions, and comparing pre- and post-treatment results. While atherectomy remains a physician-controlled intervention, AI can strengthen decision support by improving consistency in lesion characterization and helping match device choice to anatomy and risk profile.

The cumulative impact of artificial intelligence is expected to be most visible in data integration rather than autonomous plaque removal. AI tools can combine angiographic imaging, intravascular imaging, electronic health records, comorbidity profiles, and historical procedural outcomes to support risk stratification in patients with peripheral artery disease and coronary artery disease. For atherectomy procedures, this may help identify patients at higher risk of embolization, vessel injury, restenosis, or delayed wound healing, particularly in diabetes-associated limb ischemia.

AI also supports quality improvement through registry analytics, device-use pattern recognition, and complication surveillance. In high-volume vascular centers, machine learning can identify workflow bottlenecks, procedure duration drivers, contrast use patterns, and radiation exposure trends. For industry leaders, the practical value of AI lies in creating safer, more personalized, and better-documented atherectomy pathways while ensuring that algorithmic tools remain clinically validated, transparent, and compliant with medical device regulations.

In Asia-Pacific, atherectomy device adoption is influenced by a large and aging population, rising diabetes prevalence, urban lifestyle-related cardiovascular risk, and expanding interventional cardiology and vascular surgery capacity. Countries with advanced hospital infrastructure are increasing the use of complex peripheral and coronary interventions, while emerging healthcare systems are working to improve access to endovascular therapy for limb-threatening ischemia and calcified arterial disease. Local training, affordability, procurement systems, and reimbursement coverage remain important determinants of clinical penetration.

North America remains one of the most clinically mature regions for atherectomy devices, supported by established catheterization laboratories, vascular centers, outpatient endovascular programs, specialist training, and extensive use of real-world evidence. The region’s high burden of peripheral artery disease, diabetes, chronic kidney disease, and obesity contributes to a steady need for complex lesion management. Adoption is strongly shaped by reimbursement policy, medical necessity documentation, comparative effectiveness data, and safety expectations for peripheral interventions.

Latin America is seeing gradual expansion in atherectomy procedures as tertiary hospitals and private healthcare networks strengthen cardiovascular intervention capabilities. Demand is tied to the growing burden of diabetes, hypertension, smoking-related vascular disease, and late-stage peripheral artery disease presentations. However, device costs, uneven access to specialist care, and variability in public and private reimbursement create differences in availability across countries and urban centers.

Europe demonstrates structured adoption of atherectomy devices within evidence-driven vascular care pathways, with strong emphasis on clinical guidelines, health technology assessment, operator competency, and patient safety. Western European systems generally have broader access to advanced endovascular platforms, while parts of Central and Eastern Europe continue to expand interventional infrastructure. The region’s focus on limb preservation, minimally invasive therapy, and integrated cardiovascular care supports ongoing use in carefully selected calcified lesions.

In the Middle East, demand is associated with high rates of diabetes, obesity, and cardiovascular disease, particularly in countries investing heavily in advanced hospital systems and specialist cardiovascular centers. Atherectomy adoption is concentrated in tertiary and private facilities where complex peripheral and coronary interventions are available. In Africa, access is more variable, with adoption primarily limited to major urban hospitals and specialist referral centers. The clinical need is substantial due to underdiagnosed peripheral artery disease, diabetes complications, and delayed presentation, but infrastructure, affordability, and workforce availability remain key constraints.

Within ASEAN, atherectomy device use reflects a dual healthcare environment: advanced private and tertiary public hospitals in urban hubs are adopting complex endovascular procedures, while broader regional access remains constrained by reimbursement gaps and interventional workforce distribution. The high prevalence of diabetes and smoking-related vascular disease in several member states supports the need for improved peripheral artery disease detection and limb-salvage pathways.

The GCC region is characterized by strong investment in specialty cardiovascular care, high diabetes prevalence, and growing demand for minimally invasive vascular interventions. Atherectomy adoption is supported by modern hospital infrastructure and medical tourism in selected centers, although clinical utilization depends on procurement policies, physician training, and payer authorization. Across the European Union, device adoption is influenced by harmonized medical device regulation, national reimbursement systems, guideline-based care, and health technology assessment, with a strong focus on clinical evidence and safety surveillance.

In BRICS countries, atherectomy device opportunities are shaped by large patient populations, expanding healthcare infrastructure, and rising cardiometabolic disease burden, but access varies widely between metropolitan centers and underserved regions. Cost sensitivity, domestic procurement priorities, and specialist availability play a major role in adoption. G7 countries generally have advanced cardiovascular intervention ecosystems, strong regulatory oversight, and established use of imaging-guided procedures, making evidence generation, training, and health-economic justification central to continued utilization. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where medical readiness, advanced hospital infrastructure, and standardized quality systems support adoption, although reimbursement and national clinical guidelines continue to determine procedural volumes and device choice.

The United States has a well-developed atherectomy device environment supported by high procedure capacity, ambulatory endovascular centers, vascular specialists, and broad experience in treating peripheral artery disease, particularly calcified femoropopliteal and below-the-knee lesions. Utilization is closely tied to payer scrutiny, documentation standards, clinical appropriateness, and real-world outcomes. Canada shows more centralized adoption through hospital-based specialist programs, with provincial reimbursement structures and health technology evaluation influencing availability. Mexico’s adoption is concentrated in major urban hospitals and private networks, where cardiovascular disease and diabetes are increasing demand for advanced endovascular treatment.

Brazil is the most prominent Latin American setting for advanced vascular interventions, with tertiary hospitals driving adoption, although public-private access gaps remain significant. In the United Kingdom, atherectomy use is governed by evidence-based clinical governance, specialist referral pathways, and cost-effectiveness considerations. Germany has strong interventional capacity, high procedural sophistication, and broad use of imaging and catheter-based technologies, making it a key European setting for complex lesion treatment. France emphasizes structured reimbursement, clinical evaluation, and specialist vascular care, while Italy and Spain show adoption through experienced cardiovascular centers managing aging populations and diabetes-related vascular complications.

Russia’s atherectomy device access is shaped by major urban cardiovascular centers, procurement mechanisms, and regional healthcare variability. China is expanding endovascular capabilities rapidly, driven by a large cardiovascular patient base, hospital modernization, and rising clinician experience, though access differs across provinces and hospital tiers. India faces a substantial burden of diabetes and peripheral vascular disease, with adoption growing in metropolitan cardiac and vascular centers while affordability and awareness remain limiting factors. Japan has sophisticated cardiovascular infrastructure, an aging population, and strong emphasis on device quality and procedural precision, supporting selective use in complex calcified lesions. Australia benefits from advanced specialist care and established cardiovascular services, with adoption guided by reimbursement and clinical evidence. South Korea combines modern hospital infrastructure, strong interventional expertise, and high technology acceptance, supporting uptake in specialized centers treating complex arterial disease.

Industry leaders in atherectomy devices should prioritize clinical evidence generation that demonstrates safety, procedural efficiency, lesion-specific value, and patient-centered outcomes such as symptom improvement, wound healing, limb preservation, and reduced repeat intervention. Evidence strategies should include real-world registries, imaging-defined lesion subsets, long-term follow-up, and transparent reporting of complications, especially for calcified peripheral artery disease and high-risk diabetic patients.

Product development should focus on improved deliverability, controlled plaque modification, reduced embolic risk, compatibility with imaging-guided workflows, and simplified operation across different care settings. Training remains a strategic differentiator: structured physician education, simulation-based learning, case selection guidance, and complication management protocols can improve outcomes and support responsible adoption.

Commercial teams should align market access strategies with payer expectations, national reimbursement requirements, and clinical guideline trends. In emerging regions, partnerships with hospitals, professional societies, and training centers can accelerate capability building, while affordability models and service support can improve access. Leaders should also prepare for AI-enabled workflows by ensuring device data interoperability, cybersecurity, regulatory compliance, and clinically validated decision-support integration.

The research methodology for atherectomy devices combines secondary research, primary validation, and analytical triangulation to assess clinical, technological, regulatory, and commercial dynamics without relying on speculative sizing. Secondary research includes review of peer-reviewed clinical literature, regulatory databases, medical device guidance documents, clinical practice guidelines, reimbursement policies, disease burden publications, public health datasets, and hospital procedure trends where available.

Primary insights are derived from structured discussions with vascular surgeons, interventional cardiologists, interventional radiologists, hospital procurement specialists, reimbursement experts, and device technology stakeholders. These interviews help validate device adoption drivers, barriers, procedural preferences, regional access differences, and unmet clinical needs. Analytical triangulation is then used to reconcile clinical evidence, real-world practice patterns, regulatory developments, and payer behavior.

The methodology emphasizes verified and data-backed interpretation, with particular attention to peripheral artery disease prevalence, diabetes-related vascular complications, calcified lesion management, endovascular intervention trends, and safety outcomes. All conclusions are assessed for consistency across reliable sources, clinical plausibility, and relevance to strategic decision-making in the atherectomy devices ecosystem.

Atherectomy devices are increasingly important in the management of complex atherosclerotic disease, particularly when calcified lesions limit the effectiveness of conventional balloon angioplasty or stent delivery. The industry is moving toward precision vessel preparation, image-guided intervention, AI-supported decision-making, and stronger clinical governance. Regional adoption varies according to healthcare infrastructure, reimbursement, specialist availability, training, and disease burden, with advanced systems emphasizing evidence-based utilization and emerging markets focusing on access expansion.

The most successful stakeholders will be those that combine technological reliability with robust clinical data, disciplined training, workflow integration, and payer-aligned value demonstration. As peripheral artery disease, diabetes, and aging-related vascular complications continue to challenge healthcare systems, atherectomy devices will remain a key component of minimally invasive vascular care when used in appropriately selected patients and supported by high-quality procedural standards.